Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?

Basit Öğe Kaydı
dc.contributor.authorAlaşan, Fatih
dc.contributor.authorBalbay, Ege Güleç
dc.contributor.authorCangür, Şengül
dc.contributor.authorBalbay, Öner Abidin
dc.contributor.authorAydın, Leyla Yılmaz
dc.contributor.authorAnnakkaya, Ali Nihat
dc.date.accessioned2020-04-30T23:31:56Z
dc.date.available2020-04-30T23:31:56Z
dc.date.issued2019
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionAlasan, Fatih/0000-0003-0935-5927en_US
dc.descriptionWOS: 000490688100001en_US
dc.descriptionPubMed: 31615316en_US
dc.description.abstractIntroduction: The aim of this study was to present the follow-up results of 110 patients who were given anti-tumor necrosis factor alpha (TNF-?) therapy for rheumatic and dermatologic diseases in a country with a high rates of active and latent tuberculosis bacillus infection. Material and Methods: Between February 2008 and January 2015, 110 cases in the age range of 23?77 who are using anti-TNF-? were included in the study retro-prospectively. Results: 52.7% of them (n?=?58) were male. The most common diagnoses were rheumatoid arthritis (42.7%) and ankylosing spondylitis (38.2%). Most frequently given treatment were infliximab 37.3% and etanercept 30.9%, respectively. The 65 patients whose first tuberculin skin test (TST) value ?5?mm and above? was started daily 300?mg INH prophylaxis for 9?months but 3 patients had not been started because of refusing treatment. In only one case chemoprophylaxis has had to be interrupted because of high liver function test due to the INH prophylaxis. TST conversion was observed in 14 patients. Further follow-up, it was observed that 4 patients had TST's positivity. Isoniazide (INH) prophylaxis was started these 18 patients (42.9%). Although INH prophylaxis has been given in two patients, they developed active tuberculosis in follow-up. Conclusion: Considering the INH resistance in our country, all patients especially the ones with residual lesion and history of previous exposure, should be followed up closely during the anti-TNF-? treatment.en_US
dc.identifier.doi10.1080/13685538.2019.1678582en_US
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1080/13685538.2019.1678582
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4541
dc.identifier.wosWOS:000451979404055en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAging Maleen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti TNF-alphaen_US
dc.subjecttuberculosisen_US
dc.subjectisoniaziden_US
dc.titleShould isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4541.pdf
Boyut:
698.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu